3. Tuberous Sclerosis (Epiloia)
Autosomal dominant inherited neurocutaneous
disorder
Characterized by seizures, mental retardation
and skin manifestations with variable
expressivity
Given the eponym epiloia – epilepsy, low
intelligence and adenoma sebaceum
4. Tuberous Sclerosis (Epiloia)
½ have normal intelligence.
¼ do not have fits.
The cutaneous changes may be the only
presenting symptom.
Hamartomas are described in nearly all organ
except skeletal muscles.
Both sexes are affected equally.
60% are a result of mutations.
5. Tuberous Sclerosis (Epiloia)
There are 5 skin stigmata:
An ovoid ash-leaf patch of hypopigmentation
Adenomata sebaceum (angiofibromata)
Periungual fibromata
Shagreen patches (connective tissue naevi)
Fibromatous nodules
6. Ash-leaf Patch
Appears during infancy
Differs from vitiligo in that
melanocytes are present
in normal numbers but
contain few
melanosomes
7. Adenomata Sebaceum
(Angiofibromata)
Appear in childhood from
5 years onward
Occur on the face
around the sides of the
nose but may also occur
on the chin, cheeks and
forehead
11. Management
Diagnosis is usually straightforward.
Computerized axial tomography aids diagnosis
as intraventricular calcified nodules may be
found even in infants
No specific treatment but genetic counselling is
essential.
12. Neurofibromatosis
A variety of neurocutaneous syndromes
associated with:
café-au-lait macules
axillary and perineal freckling
Lisch nodules
Neurofibromata
other abnormalities
14. Neurofibromatosis – Clinical
Features
Café-au-lait patches (6 or more necessary for
the diagnosis)
Axillary and perineal freckling (Crowe’s sign)
Lisch nodules (dome-shaped, translucent
papules up to 2 mm in size in the iris)
Neurofibromata of the skin
19. Neurofibromatosis – Systemic
Features
Intracranial neurofibromata of cranial nerves,
spinal cord or peripheral nerves
Sarcomatous change may occur in any
neurofibroma
Many other associated disorders are described,
particularly endocrine and bony defects
20. Management
Genetic counselling.
Investigate and follow-up for underlying
endocrine disorders and bony defects.
Follow-up for malignant change in lesions.
Only remove lesions if bothersome or malignant
change suspected.